ArticleProceedings of the National Academy of Sciences of the United States of America2021
Killing of Gram-negative and Gram-positive bacteria by a bifunctional cell wall-targeting T6SS effector.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Bacterial weaponry and the ecological factors of competitive success.Essays in biochemistry · 2026Review
- Specific and broad-spectrum antibacterial effectors of type VI secretion system drive competition ofMicrobiology spectrum · 2026Article
- Therapeutic significance of surface-exposed virulence factors in Acinetobacter baumannii pathogenicity.Molecular biology reports · 2026Review
- Gene-in-gene coding generates dual-isoform Fha condensates to control type VI secretion system assembly.Nature communications · 2026Article
- Neisseria subflava Type 6 Secretion System competition with bacterial and fungal species.Applied microbiology and biotechnology · 2026Article
- Pan-genome insights into type VI secretion systems and their functional repertoires inmSystems · 2026Article
- The type VI secretion system and associated effector proteins.Nature reviews. Microbiology · 2026Review
- Reprogrammed SimCells for antimicrobial therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The type VI secretion system of Acinetobacter: mechanisms, biology and therapeutic potential.Communications biology · 2026Review
- Effector conformational plasticity enables lineage-specific secretion via Hcp heterohexamers in gut symbionts.Nature communications · 2026Article
- The Type VI secretion system in enteric pathogen colonization: molecular mechanisms, ecological dynamics, and therapeutic potential.Frontiers in microbiology · 2026Review
- TssW-PpkA-Fha axis controls the positioning and initiation of the type VI secretion system inmBio · 2025Article
- Dissecting the antibacterial functions of the T6SS-2 cluster inApplied and environmental microbiology · 2025Article
- CommensalGut · 2025Article
- Review
- T6SS-mediated competition bymSystems · 2025Article
- Type VI secretion system activity at lethal antibiotic concentrations leads to overestimation of weapon potency.Microbiology (Reading, England) · 2025Article
- Two cysteines control Tse1 secretion by H1-T6SS in Pseudomonas aeruginosa.Protein science : a publication of the Protein Society · 2025Article
- An interbacterial cysteine protease toxin inhibits cell growth by targeting type II DNA topoisomerases GyrB and ParE.PLoS biology · 2025Article
- Genomic Repertoire of Twenty-Two Novel Vibrionaceae Species Isolated from Marine Sediments.Microbial ecology · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The type VI secretion system (T6SS) is a powerful tool deployed by Gram-negative bacteria to antagonize neighboring organisms. Here, we report that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.